Short Interest in Forte Biosciences, Inc. (NASDAQ:FBRX) Decreases By 75.6%

Forte Biosciences, Inc. (NASDAQ:FBRX) saw a large decrease in short interest in October. As of October 31st, there was short interest totalling 1,000 shares, a decrease of 75.6% from the October 15th total of 4,100 shares. Currently, 0.1% of the company’s stock are sold short. Based on an average trading volume of 12,400 shares, the short-interest ratio is currently 0.1 days.

Forte Biosciences Stock Down 0.1 %

Shares of Forte Biosciences stock traded down $0.01 on Wednesday, reaching $5.67. The stock had a trading volume of 1,701 shares, compared to its average volume of 4,405. The company has a 50 day moving average price of $5.60 and a 200 day moving average price of $2.21. Forte Biosciences has a 1 year low of $4.11 and a 1 year high of $21.25.

Forte Biosciences (NASDAQ:FBRX) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.11). On average, sell-side analysts predict that Forte Biosciences will post -22.5 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Chardan Capital reissued a “buy” rating and issued a $3.00 price objective on shares of Forte Biosciences in a research note on Monday, August 19th.

Forte Biosciences Company Profile

Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.